Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side BrokeragesDefense World · 6 days ago
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a BetZacks Investment Research · Oct 14, 2026
Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock saleDefense World · Oct 12, 2026
Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company StockDefense World · Oct 8, 2026
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesGlobeNewsWire · Oct 6, 2026
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027Seeking Alpha · Oct 6, 2026Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$2.06 | -$1.97 | Beat |
| May 6, 2026 | -$1.78 | -$2.30 | Miss |
| Feb 24, 2026 | -$1.53 | -$1.80 | Miss |
| Nov 4, 2025 | -$1.27 | -$1.56 | Miss |
| Aug 6, 2025 | -$1.12 | -$1.22 | Miss |
| May 7, 2025 | -$1.02 | -$1.04 | Miss |